Dong-A Makes Formal Transition into Biosimilars With $72 Million Plant
This article was originally published in PharmAsia News
Executive Summary
Dong-A Pharmaceutical, South Korea's largest generics maker, plans its initial step into producing biosimilars by breaking ground on a $72 million plant through its partnership with Japan's Meiji Seika Pharma.